Antibody fusion with IL-12 proteins with disrupted heparin-binding activity
Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides.
1. A polypeptide which comprises an antibody sequence, said antibody sequence specific for a tumor associated antigen, linked or fused to a modified cytokine which (a) has a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to an unmodified heparin binding region of the wild type cytokine corresponding to the modified cytokine, and (b) exhibits immunostimulatory activity which is the same, more than, or less than that of the wild-type cytokine, wherein the wild type cytokine is IL-12.
2. The polypeptide of claim 1 , wherein
the unmodified heparin binding region consists of
VQVQGKSKREKK,
(SEQ ID NO: 10)
VQAQGKNNREKK,
(SEQ ID NO: 11)
VQVQGKNKREKK,
(SEQ ID NO: 12)
VRIQRKKEKMKE
(SEQ ID NO: 13)
or
VRIQRKKEKTKE.
(SEQ ID NO: 14)
3. The polypeptide of claim 1 , wherein the antibody sequence is that of a human antibody or a human chimeric antibody.
4. The polypeptide of claim 1 , wherein the wild type cytokine is a human cytokine.
5. The polypeptide of claim 1 , wherein the modified heparin binding region does not significantly or substantially reduce the immunostimulatory activity of the modified cytokine.
6. The polypeptide of claim 1 , wherein the modified heparin binding region of the polypeptide consists essentially of or consists of the following formula I:
V-X1-X2-Q-X3-K*-X4-X5-X6-X7-K*-X8 (I)
wherein X1 is R or Q,
X2 is V, A, or I,
X3 is G or R*,
X4 is S, N, or K*,
X5 is K*, N, or E,
X6 is R or K,
X7 is E, M, or T, and
X8 is K* or E, and
wherein one or more amino acid residues designated with an “*” are substituted with a non-polar amino acid residue selected from the group consisting of A, G, I, L, M, F, P, and V, and wherein the modified cytokine having the modified heparin binding region exhibits a decrease in heparin binding as compared to the corresponding wild type cytokine which is IL-12.
7. The polypeptide of claim 6 , wherein the modified cytokine further comprises a first amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to KYENYTSSFFIRDIIKPDPPKNLQ (SEQ ID NO:8), and/or a second amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to VEVSWEYPDTWSTPHSYFSL (SEQ ID NO:9).
8. A composition or kit which comprises the polypeptide according to claim 6 .
9. The polypeptide of claim 3 , wherein the antibody is specific for epidermal growth factor receptor (EGFR), transferrin receptor (CD71), mucin 1 (MUC1), prostate-specific membrane antigen (PMSA), CD19, CD20, CD33, CD40, CD52, or HER2/neu.
10. A polypeptide which comprises an antibody linked or fused to a modified cytokine which has a modified heparin binding region, wherein
said antibody is specific for an antigen associated with a tumor;
said modified heparin binding region comprises the following formula I:
V-X1-X2-Q-X3-K*-X4-X5-X6-X7-K*-X8 (I)
wherein X1 is R or Q,
X2 is V, A, or I,
X3 is G or R*,
X4 is S, N, or K*,
X5 is K*, N, or E,
X6 is R or K,
X7 is E, M, or T, and
X8 is K* or E, and
wherein one or more amino acid residues designated with an “*” are substituted with a non-polar amino acid residue selected from the group consisting of A, G, I, L, M, F, P, and V; and
said modified cytokine having the modified heparin binding region exhibits a decrease in heparin binding as compared to the corresponding wild type cytokine which is IL-12.
11. The polypeptide of claim 10 , wherein the antibody is specific for epidermal growth factor receptor (EGFR), transferrin receptor (CD71), mucin 1 (MUC1), prostate-specific membrane antigen (PMSA), CD19, CD20, CD33, CD40, CD52, or HER2/neu.
12. The polypeptide of claim 10 , wherein the modified cytokine further comprises a first amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to KYENYTSSFFIRDIIKPDPPKNLQ (SEQ ID NO:8), and/or a second amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to VEVSWEYPDTWSTPHSYFSL (SEQ ID NO:9).
13. The polypeptide of claim 10 , wherein the one or more amino acid residues designated with an “*” are alanine.
14. The polypeptide of claim 10 , wherein amino acid residue X3 is alanine.
15. A composition or kit which comprises the polypeptide according to claim 10 .
16. The polypeptide of claim 6 , wherein the one or more amino acid residues designated with an “*” are alanine.
17. The polypeptide of claim 6 , wherein amino acid residue X3 is alanine.